Patients who received the new drug Bendavia before undergoing angioplasty or stent implantation after a heart attack showed no significant reduction in scarring compared to patients given a placebo, according to a new study.

he Sapien 3 heart valve (Edwards Lifesciences) demonstrated lower death, stroke and paravalvular leak rates than earlier generation devices in patients at high risk for surgery and showed encouraging results in intermediate-risk patients, according to research presented at the 2015 American College of Cardiology (ACC) Annual Scientific Session.

A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing angioplasty but was associated with higher rates of moderate to severe bleeding, according to an analysis of data from a terminated Phase III trial presented at the American College of Cardiology’s 64th Annual Scientific Session. The study was officially halted in August due to an excess of severe allergic reactions, so authors caution that the data should be considered exploratory given the early termination.

The U.S. Food and Drug Administration (FDA) announced its latest efforts in supporting the Bonn Call for Action, an international list of priorities for radiation protection in medicine for the next decade.

Clearing blood clots (thrombectomy) from coronary arteries in about 20 percent of patients undergoing angioplasty appears to increase the risk of stroke without providing the intended benefit, according to a study presented at the 2015 American College of Cardiology (ACC) annual meeting.